We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pascal’s wages

2 February 2017 By Neil Unmack

Pascal Soriot’s incentive scheme hinges on earnings hitting $4.20 a share in 2017. The UK pharma now thinks it won’t. The hope is investors now focus on Astra’s need for its cancer drug to work – rather than the risk of big EPS-boosting M&A to meet a spurious pay target.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)